The Effects of Telmisartan and Its Combinations on Office Blood Pressure: Results of Prospective Observational Study TAINA
https://doi.org/10.20996/1819-6446-2020-04-07
Abstract
Aim. To evaluate the effectiveness and safety of telmisartan, used in monotherapy or in combination with hydrochlorothiazide or amlodipine, in real clinical practice in patients with diagnosed arterial hypertension who have not reached the target levels of blood pressure (BP).
Material and methods. The study was a non-intervention, prospective, multicenter, comparative, observational, epidemiological program, which was carried out in Russian medical institutions. The total patient population in which the prescribed therapy was administered included 1933 people (758 men and 1175 women, mean age 57.0-59.3 years). Participants were followed-up for 12 weeks. The change in office BP was evaluated on the 4th and 12th week.
Results. Significant (p<0.001 in all cases) change in office BP compared with the initial data were recorded in all study groups of therapy already at 4 weeks of treatment and became even more pronounced at 12 weeks. In the telmisartan monotherapy group, BP decreased from 155.7±10.7/92.2±7.6 mm Hg to 131.4±12.1/80.8±7.3 mm Hg at the end of the 4th week and to 125.3±7.6/78.2±6.1 mm Hg – at the end of the 12th week. Similarly, after treatment with the combination of telmisartan and hydrochlorothiazide, BP decreased from 162.7±12.6/94.3±7.9 mm Hg to 133.2±12.5/81.6±8.4 mmHg at the end of the 4th week and to 126.0±7.8/78.4±6.7 mm Hg – at the end of the 12th week. In telmisartan/amlodipine group, a decrease in BP also occurred, from 162.5±13.2/94.6±8.6 mm Hg to 132.8±14.5/81.3±7.5 mm Hg on the 4th week and to 125.4±8.7/78.4±5.6 mm Hg at the end of follow up (12 weeks). The proportion of patients who reached the target BP (<140/90 mm Hg) after treatment with telmisartan as monotherapy was 91.7%, after treatment with telmisartan+hydrochlorothiazide – 89.6%, after treatment with telmisartan+amlodipine – 92.8%. Throughout the program, prescribed therapy was well tolerated by patients. During the study, 47 adverse events (AEs) were recorded in 36 patients: 31 AEs with telmisartan monotherapy, 5 AEs with telmisartan/hydrochlorothiazide combination, and 11 AEs with telmisartan/amlodipine combination. Most of the AEs registered during the trial resolved by the end of the study, in four cases the date of AEs resolve is unknown, in two cases, at the time of completion of the study, AEs continued.
Conclusion. In the TAINA study a high antihypertensive efficacy and a comparable favorable safety and tolerability profile of telmisartan, used as monotherapy and in combination with hydrochlorothiazide or amlodipine was determined.
About the Authors
O. D. Ostroumova
Russian Medical Academy of Continuous Professional Education;
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Olga D. Ostroumova– MD, PhD, Professor, Head of Chair of Therapy and Polymorbid Pathology, Russian Medical Academy of Continuous Professional Education; Professor, Chair of Clinical Pharmacology and Propaedeutics of Internal Medicine, Sechenov University
Barrikadnaya ul. 2/1, Moscow, 125993,
Trubetskaya ul. 8-2, Moscow, 119991
A. I. Kochetkov
Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Alexey I. Kochetkov – MD, PhD, Associate professor, Chair of Therapy and Polymorbid Pathology
Barrikadnaya ul. 2/1, Moscow, 125993
F. T. Ageev
National Medical Research Center of Cardiology
Russian Federation
Russian Federation
Fail T. Ageev– MD, PhD, Professor, Head of Scientific Dispensary Department, Research Institute of Clinical Cardiology named after A.L. Myasnikov
Tretya Cherepkovskaya ul. 15A, Moscow, 121552
G. S. Anikin
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Georgy S. Anikin– MD, PhD, Associate Professor, Chair of Clinical Pharmacology and Propaedeutics of Internal Diseases
Trubetskaya ul. 8-2, Moscow, 119991
E. Kh. Akhmetzyanova
Bashkir State Medical University
Russian Federation
Russian Federation
Elmira Kh. Akhmetzyanova– MD, PhD, Professor, Chair of Therapy and Occupational Diseases
Lenina ul. 3, Ufa, Republic of Bashkortostan, 450008
E. I. Bezuglova
City Outpatient Сlinic №5
Russian Federation
Russian Federation
Elena I. Bezuglova– MD, Deputy Chief for Medical Part, Kursk City Polyclinic №5
Zapolnaya ul. 43A, Kursk, 305040
A. B. Bekoeva
City Consultative and Diagnostic Center №1
Russian Federation
Russian Federation
Anzhela B Bekoeva– MD, Cardiologist
Siqueirosa ul. 10, St. Petersburg, 194354
N. Yu. Borovkova
Privolzhsky Research Medical University
Russian Federation
Russian Federation
Natalia Yu. Borovkova– MD, PhD, Professor, Chair of Hospital Therapy named after V.G. Vogralika
Mininа and Pozharskogo ploschad 10/1, Nizhny Novgorod, 603005
N. G. Vinogradova
Privolzhsky Research Medical University
Russian Federation
Russian Federation
Nadezhda G. Vinogradova– MD, PhD, Assistant, Chair of Internal Diseases
Mininа and Pozharskogo ploschad 10/1, Nizhny Novgorod, 603005
E. V. Gorbunova
Research Institute for Complex Issues of Cardiovascular Diseases
Elena V. Gorbunova– MD, PhD, Head of Polyclinic, Kemerovo Cardiology Dispensary; Leading Researcher, Laboratory of Cardiac Arrhythmias and Artificial Cardiac Pacemakers, Department for Diagnosis of Cardiovascular Diseases, Research Institute for Complex Issues of Cardiovascular Diseases
Sosnovy bulv. 6, Kemerovo, 650002
A. A. Goryacheva
Medical and Diagnostic Clinic “CardioVita”;
Smolensk State Medical University
Anna A. Goryacheva– MD, PhD, Professor, Chair of Therapy, Ultrasound and Functional Diagnostics, Smolensk State Medical University; Chief-Physician, “KardioVita” Clinic
Novo-Kievskaya ul. 9A, Smolensk, 214018,
Krupskoi ul. 28, Smolensk, 214019
E. S. Zhugrova
Multidisciplinary Medical Diagnostic Center “MSCh 157”
Elena S. Zhugrova– MD, PhD, Physician
Warsawskaya ul. 100, St. Petersburg, 196066
O. A. Kislyak
Pirogov Russian National Research Medical University
Oksana A. Kislyak– MD, PhD, Professor, Head of Chair of Faculty Therapy
Ostrovityanova ul. 1, Moscow, 117997
S. M. Klyashev
Tyumen State Medical University
Sergey M. Klyashev– MD, PhD, Professor, Head of Chair of Therapy with Courses of Endocrinology, Functional and Ultrasound Diagnostics
Odesskaya ul. 54, Tyumen, 625023
V. P. Kuzmin
Samara Regional Clinical Cardiology Dispensary
Vladimir P. Kuzmin– MD, PhD, Head of Consultative and Rehabilitation Department
Aerodromnaya ul. 43, Samara, 443070
A. A. Lipchenko
“New Hospital”;
Ural State Medical University
Alexander A. Lipchenko – MD, PhD, Associate Professor, Chair of Therapy, Faculty of Continuing Education and Professional Retraining, Ural State Medical University; Head of Cardiology Service, “New Hospital”
Zavodskaya ul. 29, Ekaterinburg, 620109,
Repina ul. 3, Ekaterinburg, 620028
G. V. Matyushin
Regional Clinical Hospital
Gennady V. Matyushin– MD, PhD, Professor, Сardiologist
Partizana Zheleznyaka ul. 3a, Krasnoyarsk, 660022
E. A. Mikhailova
Saratov City Outpatient Clinic №2
Elena A. Mikhailova– MD, Cardiologist, Head of Cardiology Unit
Zheleznodorozhnaya ul. 61/69, Saratov, 410005
V. A. Nevzorova
Pacific State Medical University
Vera A. Nevzorova– MD, PhD, Professor, Director of Institute of Therapy and Instrumental Diagnostics
Ostryakova prosp. 2, Vladivostok, Primorsky Territory, 690002
A. G. Obrezan
International Medical Center SOGAZ;
St. Petersburg State University
Andrey G. Obrezan– MD, PhD, Professor, Head of Chair of Hospital Therapy, St. Petersburg State University; Chief-Physician of Group of Clinics “Sogaz Medicine”, SOGAZ International Medical Center
Cheboksarsky per. 1/6, St. Petersburg, 191186,
Universitetskaya nab. 7-9, St. Petersburg, 199034
T. A. Petrichko
City Outpatient Clinic №3;
Institute for Advanced Training of Health Workers of the Khabarovsk Territory
Tatiana A. Petrichko– MD, PhD, Professor, Chair of General Medical Practice and Preventive Medicine, Institute for Advanced Training of Health Workers of the Khabarosvsk Territory; Head of Cardiology Department, City Polyclinic №3
Dikopoltseva ul. 34, Khabarovsk, 680000,
Krasnodarskaya ul. 9, Khabarovsk, 680009
M. M. Petrova
Krasnoyarsk State Medical University named after Prof. V.F. Voino-Yasenetsky
Marina M. Petrova– MD, PhD, Professor, Head of Chair of Outpatient Therapy and Family Medicine
Partizana Zheleznyaka ul. 1, Krasnoyarsk, 660022
A. N. Reider
State Novosibirsk Regional Clinical Hospital
Tatiana N. Reider– MD, Head of Department of Emergency Cardiology, Regional Vascular Center №2
Nemirovicha-Danchenko ul. 130, Novosibirsk, 630087
A. N. Repin
Research Institute of Cardiology
Alexey N. Repin– MD, PhD, Professor, Head of Department of General Clinical Cardiology and Epidemiology of Cardiovascular Diseases
Kievskaya ul. 111A, Tomsk, 634012
V. I. Sadovoy
O.N. Semashko Republican Clinical Hospital
Valery I. Sadovoy– MD, PhD, Head of Department of Cardiology
Kievskaya ul. 69, Simferopol, Republic of Crimea, 295017
N. P. Sanina
M.F. Vladimirsky Moscow Regional Clinical Research Institute
Natalia P. Sanina– MD, PhD, Professor, Chair of Therapy
Schepkina ul. 61/2, Moscow, 129110
A. E. Skripchenko
Novokuznetsk City Clinical Hospital №1;
Novokuznetsk State Institute of Advanced Medical Studies – Branch of Russian Medical Academy of Continuing Professional Education
Alla E. Skripchenko– MD, PhD, Associate Professor, Chair of Cardiology, Novokuznetsk State Institute of Advanced Medical Studies – Branch of Russian Medical Academy of Continuing Professional Education
Bardina pr. 28, Novokuznetsk, Kemerovo Region, 654057,
Stroiteley prosp. 5, Novokuznetsk, Kemerovo Region, 654005
R. I. Stryuk
A.I. Yevdokimov Moscow State University of Medicine and Dentistry
Raisa I. Stryuk– MD, PhD, Professor, Head of Chair of Propaedeutics of Internal Diseases and Rheumatology, Faculty of Dentistry
Delegatskaya ul. 20/1, Moscow, 127423
I. V. Faiyance
Regional Clinical Cardiology Dispensary
Irina V. Faiyance– MD, Head of Cardiology Department №2
Prigorodnaya ul. 224a, Stavropol, 355026
L. A. Khaisheva
Rostov State Medical University
Larisa A. Khaisheva– MD, PhD, Professor, Chair of Internal Medicine №4
Suvorova ul. 119, Rostov-on-Don, 344022
N. R. Khasanov
Kazan State Medical University
Niyaz R. Khasanov– MD, PhD, Professor, Head of Chair of Propaedeutics of Internal Diseases named after Prof. S.S. Zimnitsky
Butlerova ul. 54, Kazan, 420012
R. A. Khokhlov
Voronezh Regional Clinical Hospital №1.
Roman A. Khokhlov– MD, Head of Regional Cardiology Clinic
Moskovsky prosp. 151, Voronezh, 394066
E. E. Tsareva
Voronezh Regional Clinical Hospital №1.
Elena E. Tsareva– MD, Cardiologist, Cardiac Surgeon
Moskovsky prosp. 151, Voronezh, 394066
A. L. Cherkashina
Irkutsk Regional Clinical Hospital
Anna L. Cherkashina– MD, PhD, Head of Cardiology Department
Karla Marksa ul. 29, Irkutsk, 664003I. I. Shaposhnik
South-Ural State Medical University
Igor I. Shaposhnik – MD, PhD, Professor, Head of Chair of Propaedeutics of Internal Diseases
Vorovskogo ul. 64, Chelyabinsk, 454092
I. A. Shelestova
Prof. S.V. Ochapovsky Research Institute – Regional Clinical Hospital №1
Inga A. Shelestova– MD, PhD, Deputy Chief-Physician for Outpatient Work
1 Maya ul. 167, Krasnodar, 350086
R. N. Shepel
National Medical Research Center for Therapy and Preventive Medicine
Ruslan N. Shepel– MD, Head of Department of Organizational and Methodological Management and Analysis of Quality of Medical Care
Petroverigsky per. 10, Moscow, 101990
E. V. Shikh
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Evgenia V. Shikh– MD, PhD, Professor, Head of Chair of Clinical Pharmacology and Propaedeutics of Internal Medicine, Director of Institute of Professional Education
Trubetskaya ul. 8-2, Moscow, 119991
D. A. Yakhontov
Novosibirsk Regional Clinical Cardiology Dispensary;
Novosibirsk State Medical University
Davyd A. Yakhontov– MD, PhD, Professor, Chair of Pharmacology, Clinical Pharmacology and Evidence-Based Medicine, Novosibirsk State Medical University; Cardiologist, Novosibirsk Regional Clinical Cardiology Dispensary
Zalesskogo ul. 6, Novosibirsk, 630047,
Krasniy prosp. 52, Novosibirsk, 630091
References
1. Williams B., Mancia G., Spiering W., et al.; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021-3104. DOI:10.1093/eurheartj/ehy339.
2. Arterial hypertension in adults. Clinical recommendations [cited by March 09, 2020]. Available from: http://cr.rosminzdrav.ru/#!/recomend/687 (In Russ.)
3. Hypertension. Fact sheets. [cited by March 9, 2020]. Available from: https://www.who.int/newsroom/fact-sheets/detail/hypertension.
4. Shalnova S.А., Konradi А.О., Balanova Y.А., et al. What factors do influence arterial hypertension control in Russia. Cardiovascular Therapy and Prevention. 2018;17(4):53-60 (In Russ.) DOI:10.15829/1728-8800-2018-4-53-60.
5. Zhou D., Xi B., Zhao M., et al. Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III Linked Mortality Study. Sci Rep. 2018;8(1):9418. DOI:10.1038/s41598-018-27377-2.
6. Teo K., Yusuf S., Sleight P., et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J. 2004;148(1):52-61. DOI:10.1016/j.ahj.2004.03.020.
7. Yusuf S., Teo K.K., Pogue J., et al.; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-59. DOI:10.1056/NEJMoa0801317.
8. Vitale C., Mercuro G., Castiglioni C., et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovascular Diabetology. 2005;4:6. DOI:10.1186/1475-2840-4-6.
9. Miura Y., Yamamoto N., Tsunekawa S., et al. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care. 2005;28(3):757-758. DOI:10.2337/diacare.28.3.757.
10. Derosa G., Cicero A.F., D'Angelo A, et al. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha. Hypertens Res. 2006;29(11):849-856. DOI:10.1291/hypres.29.849.
11. Derosa G., Cicero A.F., Bertone G., et al. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, doubleblind study. Clin Ther. 2004;26(8):1228-36. DOI:10.1016/S0149-2918(04)80049-3.
12. Kjeldsen S.E., Schumacher H., Neldam S., Guthrie R.M. Telmisartan/Hydrochlorothiazide combination therapy for the treatment of hypertension: a pooled analysis in older and younger patients. J Clin Hypertens (Greenwich). 2013;15(6):380-8. DOI:10.1111/jch.12089.
13. Neldam S., Edwards C., Jones R.; TEAMSTA-10 Investigators. Switching patients with uncontrolled hypertension on amlodipine 10mg to single-pill combinations of telmisartan and amlodipine: results of the TEAMSTA-10 study. Curr Med Res Opin. 2011;27(11):2145-53. DOI:10.1185/03007995.2011.624089.
14. Sharma A., Bagchi A., Kinagi S.B., et al. Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension. Clin Ther. 2007;29(12):2667-76. DOI:10.1016/j.clinthera.2007.12.017.
15. Goyal J., Khan Z.Y., Upadhyaya P., et al. Comparative study of high dose mono-therapy of amlodipine or telmisartan, and their low dose combination in mild to moderate hypertension. J Clin Diagn Res. 2014;8(6):HC08-11. DOI:10.7860/JCDR/2014/9352.4500.
16. Littlejohn T.W. 3rd, Majul C.R., Olvera R., et al. Results of treatment with telmisartan-amlodipine in hypertensive patients. J Clin Hypertens (Greenwich). 2009;11(4):207-13. DOI:10.1111/j.1751-7176.2009.00098.x.
17. Neutel J.M., Mancia G., Black H.R., et al. Single-pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the TEAMSTA severe HTN study. J Clin Hypertens (Greenwich). 2012;14(4):206-15. DOI:10.1111/j.1751-7176.2012.00595.x.
18. Podzolkov V.I., Tarzimanova A.I. Telmisartan in the treatment of arterial hypertension. case study. Rational Pharmacotherapy in Cardiology. 2012;8(2):201-4 (In Russ.) DOI:10.20996/1819-6446-2012-8-2-201-204.
19. Halimov Y.S., Kadin S.V. Telmisartan and new perspectives on blood pressure control and nephroprotection in patients with diabetes mellitus. Effective Pharmacotherapy. 2009;6:6-11 (In Russ.)
20. Gosse P. Left Ventricular Hypertrophy - the Problem and Possible Solutions. The Journal of International Medical Research. 2005;33(Suppl 1):3A-11A. DOI:10.1177/14732300050330S102.
21. Galzerano D., Capogrosso C., Di Michele S., et al. New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vasc Health Risk Manag. 2010;6:113-33. DOI:10.2147/vhrm.s7857.
22. Ragot S., Ezzaher A., Meunier A., et al. Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE study. J Hum Hypertens. 2002;16(12):865-73. DOI:10.1038/sj.jhh.1001494.
23. Neutel J.M., Frishman W.H., Oparil S., et al. Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. Am J Ther. 1999;6:161-6. DOI:10.1097/00045391-199905000-00007.
24. Nishimura T., Hashimoto J., Ohkubo T., et al. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements. Clin Exp Hypertens. 2005;27(6):477-89. DOI:10.1081/CEH-200067668.
25. Sasaki T., Noda Y., Yasuoka Y., et al. Comparison of the effects of telmisartan and olmesartan on home blood pressure, glucose, and lipid profiles in patients with hypertension, chronic heart failure, and metabolic syndrome. Hypertens Res. 2008;31(5):921-9. DOI:10.1291/hypres.31.921.
26. Alcocer L., Fernández-Bonetti P., Campos E., et al. Clinical efficacy and safety of telmisartan 80 mg once daily vs. atenolol 50 mg once daily in patients with mild-to-moderate hypertension. Int J Clin Pract Suppl. 2004;(145):35-39. DOI:10.1111/j.1742-1241.2004.00408.x.
27. Freytag F., Schelling A., Meinicke T., Deichsel G.; Telmisartan Hypertension Experience in a Randomized European Study Versus Atenolol Study Group. Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study. Clin Ther. 2001;23(1):108-23. DOI:10.1016/s0149-2918(01)80034-5.
28. Kakuta H., Sudoh K., Sasamata M., Yamagishi S. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res. 2005;25(1):41-46.
29. Wienen W., Hauel N., Van Meel J.C., et al. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol. 1993;110(1):245-52. DOI:10.1111/j.1476-5381.1993.tb13800.x.
Review
For citations:
Ostroumova O.D., Kochetkov A.I., Ageev F.T., Anikin G.S., Akhmetzyanova E.Kh., Bezuglova E.I., Bekoeva A.B., Borovkova N.Yu., Vinogradova N.G., Gorbunova E.V., Goryacheva A.A., Zhugrova E.S., Kislyak O.A., Klyashev S.M., Kuzmin V.P., Lipchenko A.A., Matyushin G.V., Mikhailova E.A., Nevzorova V.A., Obrezan A.G., Petrichko T.A., Petrova M.M., Reider A.N., Repin A.N., Sadovoy V.I., Sanina N.P., Skripchenko A.E., Stryuk R.I., Faiyance I.V., Khaisheva L.A., Khasanov N.R., Khokhlov R.A., Tsareva E.E., Cherkashina A.L., Shaposhnik I.I., Shelestova I.A., Shepel R.N., Shikh E.V., Yakhontov D.A. The Effects of Telmisartan and Its Combinations on Office Blood Pressure: Results of Prospective Observational Study TAINA. Rational Pharmacotherapy in Cardiology. 2020;16(2):175-190. (In Russ.) https://doi.org/10.20996/1819-6446-2020-04-07
Views:
1237
Email this article 